Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

J Cancer 2023; 14(5):874-879. doi:10.7150/jca.67189 This issue Cite

Research Paper

Survival of NSCLC Patients Treated with Cimavax-EGF as Switch Maintenance in the Real-World Scenario

Yoanna I. Flores Vega1✉, Diana L. Páramo González1, Sofía C Alsina Sarmiento1, Luis E. Alsina Tul1, Iris B. Inguanzo Valdés2, Jorge Rodríguez Machado2, Ángel Elejalde Larrinaga3, Justo E Flores Rodríguez3, Janet Lamadrid García4, Danay Corrales Otero5, Ramón Ropero Toirac6, Tania Crombet Ramos7, Elias A. Gracia Medina1

1. Department of Medical Oncology. National Institute of Oncology and Radiobiology. 29th Street, corner E, Vedado Plaza de la Revolución, Havana Cuba
2. Department of Radiotherapy. National Institute of Oncology and Radiobiology. 29th Street, corner E, Vedado Plaza de la Revolución, Havana Cuba
3. Department of Pneumology. National Institute of Oncology and Radiobiology. 29th Street, corner E, Vedado Plaza de la Revolución, Havana Cuba.
4. Department of Pathology, National Institute of Oncology and Radiobiology. 29th Street, corner E, Vedado Plaza de la Revolución, Havana Cuba.
5. Department of Imaging, National Institute of Oncology and Radiobiology. 29th Street, corner E, Vedado Plaza de la Revolución, Havana Cuba.
6. Department of Clinical Trials, National Institute of Oncology and Radiobiology. 29th Street, corner E, Vedado Plaza de la Revolución, Havana Cuba.
7. Clinical Direction. Center of Molecular Immunology, Ave 216, Esq 15. Atabey. Playa

✉ Corresponding author: Yoanna Flores Vega, MD. National Institute of Oncology and Radiobiology. 29th Street, corner E, Vedado Plaza de la Revolución, Havana, Cuba. Phone number: 537 8369114. Email: yfloressld.cu or yoannafloresvegacom More

Citation:
Flores Vega YI, Páramo González DL, Alsina Sarmiento SC, Alsina Tul LE, Inguanzo Valdés IB, Rodríguez Machado J, Elejalde Larrinaga Á, Flores Rodríguez JE, Lamadrid García J, Corrales Otero D, Ropero Toirac R, Crombet Ramos T, Gracia Medina EA. Survival of NSCLC Patients Treated with Cimavax-EGF as Switch Maintenance in the Real-World Scenario. J Cancer 2023; 14(5):874-879. doi:10.7150/jca.67189. https://www.jcancer.org/v14p0874.htm
Other styles

File import instruction

Abstract

Graphic abstract

Introduction: In Cuba, lung cancer represents the first cause of mortality for both sexes. Non-small cell lung cancer (NSCLC) is the most prevalent histology. Overall, 75-85% of NSCLC overexpress EGFR and its ligands. EGFR overexpression has been implicated in the malignant transformation by promoting cell proliferation and survival. CIMAvax-EGF is a therapeutic vaccine composed of recombinant-human EGF conjugated to a carrier protein and Montanide as an adjuvant. CIMAvax-EGF is intended to induce antibodies against self-EGF that block the EGF-EGFR interaction.

Objectives: To characterize the efficacy and safety of CIMAvax-EGF as maintenance in NSCLC patients treated in the real-world setting.

Results: 106 patients diagnosed with advanced NSCLC at the National Institute of Oncology and Radiobiology, who had at least stable disease after first-line therapy, were enrolled in the study. The initial four CIMAvax-EGF doses were administered every 2 weeks and then, patients received monthly re-immunizations. Globally, 52.8% of the patients were 65 years or older, 77.4% had an ECOG 1 and 62.3% had an adenocarcinoma. The median survival time (MST) was 14.6 months. Patients younger than 65 years had a MST of 16.7 months and subjects with ECOG 0 survived for 29 months. The median progression-free survival was 8.16 months. Overall, 36.8% and 19.8% of patients maintained disease control at 6 and 12 months, respectively. The most frequent adverse events were pain (27.3%) or induration (7.3%) at the injection site and local erythema (10.9%).

Conclusion: CIMAvax-EGF, as an EGF depleting immunotherapy used as switch-maintenance was safe and effective in patients with NSCLC.

Keywords: CIMAvax-EGF, NSCLC, EGFR, vaccine, immunotherapy

Citation styles

APA
Flores Vega, Y.I., Páramo González, D.L., Alsina Sarmiento, S.C., Alsina Tul, L.E., Inguanzo Valdés, I.B., Rodríguez Machado, J., Elejalde Larrinaga, Á., Flores Rodríguez, J.E., Lamadrid García, J., Corrales Otero, D., Ropero Toirac, R., Crombet Ramos, T., Gracia Medina, E.A. (2023). Survival of NSCLC Patients Treated with Cimavax-EGF as Switch Maintenance in the Real-World Scenario. Journal of Cancer, 14(5), 874-879. https://doi.org/10.7150/jca.67189.

ACS
Flores Vega, Y.I.; Páramo González, D.L.; Alsina Sarmiento, S.C.; Alsina Tul, L.E.; Inguanzo Valdés, I.B.; Rodríguez Machado, J.; Elejalde Larrinaga, Á.; Flores Rodríguez, J.E.; Lamadrid García, J.; Corrales Otero, D.; Ropero Toirac, R.; Crombet Ramos, T.; Gracia Medina, E.A. Survival of NSCLC Patients Treated with Cimavax-EGF as Switch Maintenance in the Real-World Scenario. J. Cancer 2023, 14 (5), 874-879. DOI: 10.7150/jca.67189.

NLM
Flores Vega YI, Páramo González DL, Alsina Sarmiento SC, Alsina Tul LE, Inguanzo Valdés IB, Rodríguez Machado J, Elejalde Larrinaga Á, Flores Rodríguez JE, Lamadrid García J, Corrales Otero D, Ropero Toirac R, Crombet Ramos T, Gracia Medina EA. Survival of NSCLC Patients Treated with Cimavax-EGF as Switch Maintenance in the Real-World Scenario. J Cancer 2023; 14(5):874-879. doi:10.7150/jca.67189. https://www.jcancer.org/v14p0874.htm

CSE
Flores Vega YI, Páramo González DL, Alsina Sarmiento SC, Alsina Tul LE, Inguanzo Valdés IB, Rodríguez Machado J, Elejalde Larrinaga Á, Flores Rodríguez JE, Lamadrid García J, Corrales Otero D, Ropero Toirac R, Crombet Ramos T, Gracia Medina EA. 2023. Survival of NSCLC Patients Treated with Cimavax-EGF as Switch Maintenance in the Real-World Scenario. J Cancer. 14(5):874-879.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use